NASDAQ:EDSA
Edesa Biotech, Inc.
Edesa Biotech, Inc. reported net income of −$7.2M in fiscal 2025.Summary generated from Edesa Biotech, Inc.'s SEC filings. Latest annual report filed Dec 12, 2025.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−99.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | n/a | n/a | n/a | n/a |
| Operating income | −24 | −18 | −9 | −7 | −8 |
| Net income | −13 | −18 | −8 | −6 | −7 |
| Free cash flow | −14 | −12 | −7 | n/a | n/a |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 4Insider transaction report
Sep 1, 2026 - 8-KEntry into a material agreement
Aug 20, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KEntry into a material agreement
Jun 11, 2026 - 8-KOther events
Jun 5, 2026 - 8-KDirector or officer change
May 29, 2026